Abstract 6P
Background
Development of an immunosuppressive pre-metastatic microenvironment is a prerequisite for lung metastasis of breast cancer. However, previous mechanisms have focused on immune cells rather than vascular endothelial cells. Our previous research has shown that tumor cell-released autophagosomes (TRAPs) preferentially reaches the lung rather than breast cancer cells in the mouse model. Could the pre-arrival of TRAPs promote the immunosuppressive pre-metastatic microenvironment by acting on endothelial cells?.
Methods
TRAPs-treated ECs were subjected to transcriptome analysis. T cell function was detected by flow cytometry after co-culture of TRAP-treated ECs with T cells in vitro. We injected TRAPs into mice via the tail vein or established endogenous Becn1 knockdown 4T1 tumor cells model which reduced TRAPs release. Flow cytometry will be used to analyze Immunosuppressive function of PVECs and the late lung metastases was monitored. Antibody blocking assay and HMGB1 knockdown cell lines were used to detect key DAMP on the surface of TRAPs. Inhibitor-treated ECs and TLR4 knockout mice were used to detect corresponding functional receptors on the surface of ECs. CD/FillpinⅢ/CPZ -treated ECs to detect the movement of the cytoskeleton. Activation of signal pathways was detected by Western blot.
Results
TRAPs from breast tumor cell lines stimulated the upregulation of PD-L1 in PVECs via a HMGB1-TLR4–MyD88–p38/STAT3 signal cascade and depended on the movement of the cytoskeleton of ECs. TRAPs-treated ECs suppressed IFN-γ secretion and proliferation of CD4+ and CD8+ T cells in vitro and in vivo. Anti-PD-L1 treatment upregulated pulmonary T-cell function and reduced lung metastasis in tumor-bearing mice.
Conclusions
These findings elucidate a novel role and mechanism of TRAPs-induced immunosuppression of vascular endothelial cells in the pre-metastatic microenvironment. TRAPs or their surface HMGB1 represent important therapeutic targets to reverse immunosuppressive formation, while also providing a new theoretical basis for the treatment of early breast cancer with PD-L1 antibodies.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Y. Wu, X. Zhou, C. Wu.
Funding
National Natural Science Foundation, China.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
341P - NUP214 gene rearrangements in leukemia patients: Case series from a single institution
Presenter: Yu Jeong Choi
Session: Poster Display
Resources:
Abstract
344P - Venetoclax and azacitidine compared with azacitidine monotherapy for acute myeloid leukemia patients: A systematic review and meta-analysis
Presenter: Azzahra Noersamsjah
Session: Poster Display
Resources:
Abstract
345P - Safety and efficacy of platinum substitution in induction chemotherapy for mantle cell lymphoma
Presenter: Omali Pitiyarachchi
Session: Poster Display
Resources:
Abstract
346P - An assessment of marrow-infiltrating T cells in early relapsed hematologic cancer patients after allogeneic hematopoietic stem cell transplantation
Presenter: Ik-Chan Song
Session: Poster Display
Resources:
Abstract
347P - New targets for adult T cell leukemia/lymphoma (ATLL): A map for ATLL immunotherapy
Presenter: Zahra Rezaei Borojerdi
Session: Poster Display
Resources:
Abstract
348P - In-depth molecular analysis in the diagnosis of lymphomas with lymphoplasmacytic differentiation may provide a more precise diagnosis and rational treatment allocation
Presenter: Ella Willenbacher
Session: Poster Display
Resources:
Abstract
349P - Overall survival and progression-free survival comparison of lenalidomide + standard therapy versus standard therapy only in indolent lymphoma: A meta-analysis
Presenter: Kevin Winston
Session: Poster Display
Resources:
Abstract
350P - Intratumoural CD66b+ to predict treatment response in diffuse large B cell lymphoma (DLBCL)
Presenter: Mita Adriani
Session: Poster Display
Resources:
Abstract
351P - Clinical features and treatment outcomes of Waldenstrom macroglobulinemia patients: A single center study
Presenter: Devi Amelia
Session: Poster Display
Resources:
Abstract
352TiP - Randomized phase III study of daratumumab (D) versus bortezomib plus D as a maintenance therapy after D-MPB for elderly or non-elderly patients refusing transplant with untreated multiple myeloma (JCOG1911, B-DASH study)
Presenter: Tomotaka Suzuki
Session: Poster Display
Resources:
Abstract